甲状腺功能减退症治疗过度与不足均与超额死亡率相关:一项基于登记资料的队列研究
该研究基于登记资料纳入235,168名在1995-2011年间至少检测过一次血清促甲状腺激素(TSH)的个体,中位随访7.2年。结果显示未治疗甲减患者全因死亡率升高(HR=1.46),而治疗者总体死亡率未升高,但治疗者TSH降低持续时间对死亡率的影响大于TSH升高持续时间,提示需密切监测甲状腺激素替代治疗。
要点
- 未治疗甲减患者全因死亡率较甲功正常对照升高(HR=1.46,95%CI 1.26-1.69)。
- 接受左甲状腺素治疗者每6个月TSH降低,死亡HR增加1.18(95%CI 1.15-1.21)。
- 治疗者TSH降低持续时间对死亡率的影响大于TSH升高持续时间。
核心结论
- 未治疗甲减患者死亡率升高,而治疗者死亡率未升高,且独立于年龄和甲减严重程度。
- 治疗者TSH降低持续时间对死亡率的影响大于TSH升高持续时间,结果强调对接受甲状腺激素替代治疗者需密切监测。
研究设计与样本
- 基于登记资料的队列研究,纳入235,168名在1995-2011年间至少有一次血清TSH检测的个体,中位随访7.2年。
- 甲减定义为半年内至少两次间隔≥14天的TSH>4.0 mIU/L,或一次TSH>4.0 mIU/L且次年有两次左甲状腺素处方配药。
- 采用多变量Cox回归分析计算全因死亡率,校正年龄、性别及基于Charlson合并症指数的合并症。
主要发现
- 未治疗甲减个体(n=673)较甲功正常对照死亡率升高(HR=1.46,95%CI 1.26-1.69,p<0.001)。
- 按轻度(TSH>4.0 mIU/L且≤10 mIU/L,p<0.001)和显著甲减(TSH>10 mIU/L,p=0.002)分层后结果仍显著。
- 治疗和未治疗甲减个体每6个月TSH升高,死亡HR均为1.05(治疗者95%CI 1.02-1.07,p<0.0001;未治疗者95%CI 1.02-1.07,p=0.0009)。
- 接受左甲状腺素治疗者每6个月TSH降低,死亡HR增加1.18(95%CI 1.15-1.21,p<0.0001),按疾病严重程度和年龄(>65岁与<65岁)分层后基本不变。
临床怎么用
- 作者认为结果强调需要对接受甲状腺激素替代治疗的个体密切监测治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study investigated the association between hypothyroidism and mortality in both treated and untreated hypothyroid patients, and the consequences of over- and under-treatment with respect to mortality. PATIENTS AND METHODS: This was a register-based cohort study of 235,168 individuals who had at least one serum thyrotropin (TSH) during 1995-2011 (median follow-up 7.2 years). Hypothyroidism was defined as at least two measurements of TSH >4.0 mIU/L within a half year spaced by at least 14 days, or one measurement of TSH >4.0 mIU/L and two filled prescriptions of levothyroxine the following year. All-cause mortality rates were calculated using multivariable Cox regression analysis adjusted for age, sex, and comorbidities using the Charlson Comorbidity Index. RESULTS: Mortality was increased in untreated hypothyroid individuals (n = 673; hazard ratio [HR] = 1.46 [confidence interval (CI) 1.26-1.69]; p < 0.001) compared to euthyroid controls. Results remained significant even when subdividing according to mild (TSH >4.0 mIU/L and ≤10 mIU/L; p < 0.001) and marked hypothyroidism (TSH >10 mIU/L; p = 0.002). Mortality was increased in both treated and untreated hypothyroid individuals for each six months a patient had increased TSH (HR = 1.05 [CI 1.02-1.07], p < 0.0001, and HR = 1.05 [CI 1.02-1.07], p = 0.0009, respectively). In patients who received levothyroxine, the HR for mortality increased by a factor 1.18 ([CI 1.15-1.21]; p < 0.0001) for each six months a patient exhibited decreased TSH. This finding was essentially unchanged after stratification by disease severity (mild or marked hypothyroidism) and age (older and younger than 65 years). CONCLUSIONS: Mortality was increased in untreated but not in treated hypothyroid individuals, independently of age and severity of hypothyroidism. Duration of decreased TSH in treated individuals had a greater impact on mortality than did duration of elevated TSH. These results stress the need for close monitoring of treatment in individuals receiving thyroid hormone replacement therapy.
引用
- Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, et al. Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study. Thyroid. 2018. PMID: 29631518. doi:10.1089/thy.2017.0517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。